Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
暂无分享,去创建一个
E. Rozeman | T. Huizinga | R. Toes | J. Haanen | J. Bakker | E. Kapiteijn | D. van der Woude | E. Verdegaal | A. Grummels | E. C. de Moel
[1] J. Schachter,et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. , 2018, Autoimmunity reviews.
[2] M. Akiyama,et al. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study , 2018, Journal of the Endocrine Society.
[3] A. Ribas,et al. Endocrinopathies with use of cancer immunotherapies , 2018, Clinical endocrinology.
[4] A. Ravaud,et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study , 2017, Annals of the rheumatic diseases.
[5] F. Guaraldi,et al. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution , 2018, Journal of Endocrinological Investigation.
[6] J. Wolchok,et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] C. Schraml,et al. Pembrolizumab‐induced hepatitis: diagnosis and treatment , 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[8] C. Garbe,et al. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. , 2017, European journal of cancer.
[9] E. Plimack,et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. , 2017, Cancer treatment reviews.
[10] J. Larkin,et al. Thyroid abnormalities following the use of cytotoxic T‐lymphocyte antigen‐4 and programmed death receptor protein‐1 inhibitors in the treatment of melanoma , 2017, Clinical endocrinology.
[11] D. Schadendorf,et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] V. Velcheti,et al. Correction: Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity , 2017, RMD Open.
[13] C. Rudin,et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Ami A. Shah,et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab , 2016, Annals of the rheumatic diseases.
[15] M. Faham,et al. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. , 2017, Cancer research.
[16] M. Faham,et al. Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients. , 2016 .
[17] T. Barnetche,et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.
[18] Paulo Luiz Carvalho Francescantônio,et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015 , 2015, Front. Immunol..
[19] Amitabh Srivastava,et al. Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases , 2015, The American journal of surgical pathology.
[20] Ritwik Pandey,et al. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy , 2015, BMJ Case Reports.
[21] N. Urgancı,et al. Antithyroid Antibodies and Thyroid Function in Pediatric Patients with Celiac Disease , 2015, International journal of endocrinology.
[22] A. Araszkiewicz,et al. Prevalence of anti-thyroid peroxidase in adults with type 1 diabetes participating in Poznań Prospective Study. , 2015 .
[23] S. H. van der Burg,et al. Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response , 2014, Science Translational Medicine.
[24] Ryan Emerson,et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.
[25] J. Anaya,et al. Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective , 2012, Arthritis.
[26] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[27] J. Kirkwood,et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.
[28] S. Aamdal,et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. , 2009, Journal of the National Cancer Institute.
[29] I. Yavaşoğlu,et al. Rheumatoid Arthritis and Anti-Thyroid Antibodies , 2009, Autoimmunity.
[30] A. Filipowicz-Sosnowska,et al. Prevalence of thyroid diseases and antithyroid antibodies in women with rheumatoid arthritis. , 2009, Polskie Archiwum Medycyny Wewnetrznej.
[31] N. Mousavinasab,et al. Thyroid function and anti-thyroid antibodies in Iranian patients with type 1 diabetes mellitus: influences of age and sex. , 2008, Iranian journal of allergy, asthma, and immunology.
[32] M. Turiel,et al. Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: Prevalence and clinical value , 2008, Autoimmunity.
[33] K. Zaletel,et al. Thyroid autoantibody production is influenced by exon 1 and promoter CTLA‐4 polymorphisms in patients with Hashimoto's thyroiditis , 2006, International journal of immunogenetics.
[34] G. Barbesino,et al. CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. , 2001, The Journal of clinical endocrinology and metabolism.
[35] G. Brabant,et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Monson,et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha. , 1991, British Journal of Cancer.
[37] M. Atkins,et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. , 1988, The New England journal of medicine.
[38] M. Feldmann,et al. ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY , 1983, The Lancet.